Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional) (345317)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next deadline: Sep 25, 2023 (Letter of inquiry)

Later deadlines: Oct 25, 2023 (Full proposal), Jan 21, 2024 (Letter of inquiry), Feb 21, 2024 (Full proposal), Sep 25, 2024 (Letter of inquiry), Oct 25, 2024 (Full proposal), Jan 21, 2025 (Letter of inquiry), Feb 21, 2025 (Full proposal)

Grant amount: Unspecified amount

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization. 

This Funding Opportunity Announcement (FOA) invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing a comprehensive understanding of the impact of sex differences on the trajectories of brain aging and disease, phenotypes of AD and AD-related dementias (ADRD) risk, individualized prevention, and responsiveness to pharmacologic and non-pharmacologic interventions. To this end, the central goal of this initiative is to develop robust research programs that will explore how genes, environment, and host factors such as hormonal status (gonadal and brain-derived) interact at various levels of biologic complexity (i.e., cell, tissue, organs/organ systems, and populations) to produce heterogeneous phenotypes of disease risk and responsiveness to prevention/therapy in AD/ADRD.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.